The benefits, costs and feasibility of a low incidence COVID-19 strategy

The Lancet Regional Health - Europe, Journal Year: 2022, Volume and Issue: 13, P. 100294 - 100294

Published: Jan. 2, 2022

In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves COVID-19 pandemic. Most countries failed to achieve immunization rates high enough avoid resurgence virus. Public health strategies for autumn winter 2021 have ranged from aiming at low incidence by re-introducing accepting levels. However, such almost certainly lead very consequences that they seek avoid: restrictions harm people economies. At incidence, important pandemic containment measure 'test-trace-isolate-support' becomes inefficient. point, spread SARS-CoV-2 its numerous harmful can likely only be controlled through restrictions. We argue all need pursue a strategy in coordinated manner. Such an endeavour successful if it is built on open communication trust.

Language: Английский

---

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

BMC Medicine, Journal Year: 2022, Volume and Issue: 20(1)

Published: Sept. 27, 2022

In vitro drug screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was conducted to investigate whether is an effective treatment for (COVID-19).This a multicenter, double-blind, randomized, parallel-group, placebo-controlled study. Patients were enrolled if they admitted hospital within 5 days of onset COVID-19 symptoms or positive test asymptomatic patients. Severe cases (e.g., those requiring oxygenation/ventilation) excluded. enrolled, and allocated each group using interactive web response system. Randomization performed minimization method with the factors medical institution, age, underlying diseases (chronic respiratory disease, chronic kidney diabetes mellitus, hypertension, cardiovascular diseases, obesity). The patients, investigators/subinvestigators, coordinators, other personnel blinded throughout administered (600 mg qid; four eight times higher than clinical doses in Japan) placebo up 14 days. primary efficacy endpoint time first two consecutive negative tests SARS-CoV-2.One-hundred fifty-five patients randomized receive (n = 78) 77). median 11.0 (95% confidence interval [CI]: 9.0-12.0) CI: 10.0-13.0) group. Conversion viral status by day observed 45 74 (60.8%) 47 (63.5%) (Bayesian) secondary (frequentist) analyses found no significant differences between groups. No additional safety concerns beyond already known identified.Camostat did not substantially reduce clearance, based on upper loads, compared treating mild moderate without symptoms.ClinicalTrials.gov, NCT04657497. Japan Registry Clinical Trials, jRCT2031200198.

Language: Английский

---

Coupled disease-vaccination behavior dynamic analysis and its application in COVID-19 pandemic

Chaos Solitons & Fractals, Journal Year: 2023, Volume and Issue: 169, P. 113294 - 113294

Published: March 2, 2023

Language: Английский

---

The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

Autoimmunity, Journal Year: 2023, Volume and Issue: 56(1)

Published: June 28, 2023

Nowadays, data concerning the risk of autoimmune disease after SARS-CoV-2 (COVID-19) vaccination is controversial. The aim this single centre prospective follow-up study was to evaluate whether healthcare workers (HCWs) vaccinated with BNT162b2 mRNA and mRNA-1273 will show a development and/or persistence autoantibodies, focussing on detection antibodies against nuclear antigens (antinuclear antibodies, ANA). We enrolled 155 HCWs, however only 108 them received third dose were considered for further analysis. Blood samples collected before vaccine inoculation (T0), at 3 (T1) 12 months (T2) first dose. All analysed presence a) ANA using indirect Immunofluorescence [IIF] (dilutions 1:80, 1:160. 1:320 1:640), anti-smooth muscle (ASMA); b) anti-myeloperoxidase (anti-MPO), anti-proteinase (anti-PR3) anti-citrullinated peptide (aCCP) [FEIA]; c) anti-phospholipid (anticardiolipin [aCL], anti-beta-2- glycoprotein I [anti-ß-2GPI] (Chemiluminescence). Line-blot technology performed following kit: EUROLINE profile plus DFS70 (IgG). Our research suggests that based anti-SARSCoV-2 vaccines can induce production de novo in 22/77(28,57%) subjects percentage positivity seems be directly correlated number expositions: 6/77 (7,79%) 2 doses; 16/77 (20,78%) doses. Since it known hyperstimulation immune system could lead autoimmunity, these preliminary results seem sustain idea might an autoinflammatory mechanism eventually disorders. However, link between diseases needs investigated.

Language: Английский

---

Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study

Epidemics, Journal Year: 2024, Volume and Issue: 46, P. 100744 - 100744

Published: Feb. 2, 2024

Non-pharmaceutical interventions (NPIs) and vaccines have been widely used to manage the COVID-19 pandemic. However, uncertainty persists regarding effectiveness of these due data quality issues, methodological challenges, differing contextual factors. Accurate estimation their effects is crucial for future epidemic preparedness. To address this, we developed a population-based mechanistic model that includes impact NPIs on SARS-CoV-2 transmission hospitalization rates. Our statistical approach estimated all parameters in one step, accurately propagating uncertainty. We fitted comprehensive epidemiological France from March 2020 October 2021. With same model, simulated scenarios vaccine rollout. The first lockdown was most effective, reducing by 84% (95% confidence interval (CI) 83-85). Subsequent lockdowns had diminished (reduction 74% (69-77) 11% (9-18), respectively). A 6 pm curfew more effective than at 8 (68% (66-69) vs. 48% (45-49) reduction), while school closures reduced 15% (12-18). In scenario without before November 2021, predicted 159,000 or 194% prediction (PI) 74-424) deaths 1,488,000 340% (136-689) hospitalizations. If available after 100 days, over 71,000 (16,507-204,249) 384,000 (88,579-1,020,386) hospitalizations could averted. results highlight substantial NPIs, including curfews, controlling also demonstrate value days objective Coalition Epidemic Preparedness Innovations (CEPI) initiative availability.

Language: Английский

---